Showing results (61-70 of 207) with videos related to

Sort By:
Pageof 21
Haematologica|June 5, 2014
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomesJohn F Seymour, Michael Pfreundschuh, Marek Trnĕný, et al.
International Journal of Cancer|September 24, 2004
Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2Frank Neumann, Claudia Wagner, Stefan Stevanovic, et al.
Arthritis Research & Therapy|December 11, 2013
Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritisLorenz Thurner, Marina Zaks, Klaus-Dieter Preuss, et al.
British Journal of Haematology|September 4, 2010
Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuriaAdnan Alahmad, Klaus-Dieter Preuss, Joachim Schenk, et al.
Cancer Science|January 6, 2011
Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myelomaSandra Grass, Shinsuke Iida, Aleksandra Wikowicz, et al.
International Journal of Cancer|February 22, 2002
Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomasRudolf Schmits, Björn Cochlovius, Gerhard Treitz, et al.
Annals of Hematology|February 25, 2009
Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigensCarsten Zwick, Klaus-Dieter Preuss, Boris Kubuschok, et al.
International Journal of Cancer|August 9, 2008
Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cellsGerhard Held, Frank Neumann, Christine Sturm, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2013
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumorsFrank Neumann, Dominic Kaddu-Mulindwa, Thomas Widmann, et al.
Cancer|August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupChristina Nickenig, Martin Dreyling, Eva Hoster, et al.
Pageof 21